Literature DB >> 33179378

2020 Innovation-Based Optimism for Lung Cancer Outcomes.

Erin L Schenk1, Tejas Patil1, Jose Pacheco1, Paul A Bunn1.   

Abstract

Lung cancer is the leading cause of cancer death in both males and females in the U.S. and worldwide. Owing to advances in prevention, screening/early detection, and therapy, lung cancer mortality rates are decreasing and survival rates are increasing. These innovations are based on scientific discoveries in imaging, diagnostics, genomics, molecular therapy, and immunotherapy. Outcomes have improved in all histologies and stages. This review provides information on the clinical implications of these innovations that are practical for the practicing physicians, especially oncologists of all specialities who diagnose and treat patients with lung cancer. IMPLICATIONS FOR PRACTICE: Lung cancer survival rates have improved because of new prevention, screening, and therapy methods. This work provides a review of current standards for each of these areas, including targeted and immunotherapies. Treatment recommendations are provided for all stages of lung cancer.
© 2020 AlphaMed Press.

Entities:  

Keywords:  Diagnosis and therapy; Lung cancer; Prevention; Screening

Year:  2020        PMID: 33179378      PMCID: PMC7930417          DOI: 10.1002/onco.13590

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  209 in total

1.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Authors:  Ji-Youn Han; Keunchil Park; Sang-We Kim; Dae Ho Lee; Hyae Young Kim; Heung Tae Kim; Myung Ju Ahn; Tak Yun; Jin Seok Ahn; Cheolwon Suh; Jung-Shin Lee; Sung Jin Yoon; Jong Hee Han; Jae Won Lee; Sook Jung Jo; Jin Soo Lee
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

2.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

4.  A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04).

Authors:  Jeffrey D Bradley; Charles B Scott; Kristie J Paris; William F Demas; Mitchell Machtay; Ritsuko Komaki; Benjamin Movsas; Philip Rubin; William T Sause
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-04-01       Impact factor: 7.038

5.  HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Authors:  Rathi N Pillai; Madhusmita Behera; Lynne D Berry; Mike R Rossi; Mark G Kris; Bruce E Johnson; Paul A Bunn; Suresh S Ramalingam; Fadlo R Khuri
Journal:  Cancer       Date:  2017-07-25       Impact factor: 6.860

6.  Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.

Authors:  Steinn Jonsson; Marileila Varella-Garcia; York E Miller; Holly J Wolf; Tim Byers; Sarah Braudrick; Porntip Kiatsimkul; Marina Lewis; Timothy C Kennedy; Robert L Keith; Johannes Bjornsson; Annette McWilliams; Stephen Lam; Fred R Hirsch; Wilbur A Franklin
Journal:  Am J Respir Crit Care Med       Date:  2007-11-07       Impact factor: 21.405

7.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

9.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

10.  Osimertinib Called "Home Run" for EGFR-Mutant NSCLC.

Authors: 
Journal:  Cancer Discov       Date:  2020-06-02       Impact factor: 39.397

View more
  4 in total

1.  A Four-Gene Prognostic Signature Based on the TEAD4 Differential Expression Predicts Overall Survival and Immune Microenvironment Estimation in Lung Adenocarcinoma.

Authors:  Xiaoxia Gong; Ning Li; Chen Sun; Zhaoshui Li; Hao Xie
Journal:  Front Pharmacol       Date:  2022-05-04       Impact factor: 5.988

2.  Effects and mechanism of miR-133a on invasion and migration of lung cancer cells.

Authors:  Bing Yu; Jinghua Pang; Jiawen You
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

3.  Comprehensive Analysis of YTH Domain Family in Lung Adenocarcinoma: Expression Profile, Association with Prognostic Value, and Immune Infiltration.

Authors:  Kuan Hu; Lei Yao; Yuanliang Yan; Lei Zhou; Juanni Li
Journal:  Dis Markers       Date:  2021-08-26       Impact factor: 3.434

4.  International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials.

Authors:  Matthew P Smeltzer; Giorgio V Scagliotti; Heather A Wakelee; Tetsuya Mitsudomi; Upal Basu Roy; Russell C Clark; Renee Arndt; Clayton D Pruett; Karen L Kelly; Peter Ujhazy; Melissa L Johnson; Yesim Eralp; Carlos H Barrios; Fabrice Barlesi; Fred R Hirsch; Paul A Bunn
Journal:  J Thorac Oncol       Date:  2022-02-17       Impact factor: 20.121

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.